James Ge, M.D., Ph.D. has been named executive vice president, chief operations and development officer responsible for global development at MicuRx. Dr. Ge has broad experience in all areas of anti-infective drug development, from discovery through international regulatory approvals.
Prior to MicuRx, he served in a variety of executive and escalating management positions at pharmaceutical and biotechnology companies including ALDEA Pharmaceuticals, Kalidex Pharmaceuticals, Calixa Pharmaceuticals (acquired by Cubist Pharmaceuticals), Forest Laboratories, Cerexa Pharmaceuticals (acquired by Forest Laboratories), Peninsula Pharmaceuticals (acquired by J&J Pharmaceuticals), Genesoft Inc, and Magainin Pharmaceuticals Inc. He has founded or co-founded several biotech franchises, and played a key role in the growth and exit of three antibiotics companies.
Zhengyu Yuan, Ph.D., president and chief executive officer of MicuRx, commented, "The addition of James Ge to our executive management team brings premier industry leadership into our clinical studies and international operations, and we look forward to relying on his insight and direction to ensure accelerated progress of MRX-I clinical studies."